Concepts (34)
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with Bree Lege's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that Bree Lege has written about over time.
AcetylationCyclin-Dependent Kinase Inhibitor p21Histone CodePlatelet Activating FactorReceptors, CXCR4Mice, Inbred NODMice, NudeMice, SCIDProstatic NeoplasmsTumor Cells, CulturedTumor MicroenvironmentXenograft Model Antitumor AssaysBiomarkers, TumorBone NeoplasmsBreast NeoplasmsNeoplasm MetastasisCell Line, TumorReceptor, ErbB-2Receptors, EstrogenReceptors, Progesterone
To see the data from this visualization as text,
click here.
| Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
|---|
| Acetylation | 1 | 2017 | 2017 | February 2017 |
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2017 | 2017 | February 2017 |
| Histone Code | 1 | 2017 | 2017 | February 2017 |
| Platelet Activating Factor | 1 | 2017 | 2017 | February 2017 |
| Receptors, CXCR4 | 1 | 2017 | 2017 | February 2017 |
| Mice, Inbred NOD | 1 | 2021 | 2021 | April 2021 |
| Mice, Nude | 1 | 2021 | 2021 | April 2021 |
| Mice, SCID | 1 | 2021 | 2021 | April 2021 |
| Prostatic Neoplasms | 1 | 2021 | 2021 | April 2021 |
| Tumor Cells, Cultured | 1 | 2021 | 2021 | April 2021 |
| Tumor Microenvironment | 1 | 2021 | 2021 | April 2021 |
| Xenograft Model Antitumor Assays | 1 | 2021 | 2021 | April 2021 |
| Biomarkers, Tumor | 2 | 2021 | 2025 | April 2023 |
| Bone Neoplasms | 2 | 2021 | 2025 | April 2023 |
| Breast Neoplasms | 2 | 2021 | 2025 | April 2023 |
| Neoplasm Metastasis | 2 | 2021 | 2025 | April 2023 |
| Cell Line, Tumor | 1 | 2025 | 2025 | March 2025 |
| Receptor, ErbB-2 | 1 | 2025 | 2025 | March 2025 |
| Receptors, Estrogen | 1 | 2025 | 2025 | March 2025 |
| Receptors, Progesterone | 1 | 2025 | 2025 | March 2025 |
To return to the timeline,
click here.